SkinHealth Systems Future Growth
Future criteria checks 0/6
SkinHealth Systems's earnings are forecast to decline at 4.8% per annum while its annual revenue is expected to grow at 2.2% per year. EPS is expected to decline by 4.3% per annum. Return on equity is forecast to be 9.5% in 3 years.
Key information
-4.8%
Earnings growth rate
-4.33%
EPS growth rate
| Personal Products earnings growth | 28.4% |
| Revenue growth rate | 2.2% |
| Future return on equity | 9.47% |
| Analyst coverage | Good |
| Last updated | 14 Jul 2026 |
Recent future growth updates
Recent updates
Narrative Update • Jul 10
SKIN: Fair Outlook Weighs Competitive Pressure Against New FDA Clearances
Analysts have trimmed their price target on SkinHealth Systems to $1.00 from $1.50, citing updated assumptions that reflect softer modeled revenue growth, a lower fair value estimate, modestly improved profit margin expectations, and a reduced future P/E multiple in light of ongoing competitive pressures in the lower end of the market. Analyst Commentary on SkinHealth Systems Recent research commentary on SkinHealth Systems points to a more cautious stance, with several bearish analysts revisiting their models after the latest quarterly update and trimming valuation assumptions to reflect ongoing competitive and execution risks.
Narrative Update • Jun 26
SKIN: Clearer Device Positioning And Margins Will Support Future Upside
Analysts have reduced the SkinHealth Systems price target to $2.00 from $3.50, citing updated models that reflect higher discount rates, softer revenue growth assumptions, lower expected profit margins, and a much higher projected future P/E multiple in light of rising competitive pressures across the beauty device market. Analyst Commentary Recent Street research on SkinHealth Systems highlights that analysts are recalibrating their expectations while still pointing to potential areas where the stock could regain investor interest.
Narrative Update • Jun 06
SKIN: Future Returns Will Hinge On Delivering FY26 EBITDA Under Competitive Pressure
Narrative Update on SkinHealth Systems Analysts have trimmed the SkinHealth Systems price target from $2.50 to $2.00, citing updated models that factor in recent earnings, ongoing competitive pressure at the lower end of the market, and adjusted long term assumptions for revenue growth, profit margins, discount rate and future P/E. Analyst Commentary Recent research commentary around SkinHealth Systems centers on recalibrated price targets, revised models following quarterly updates, and an ongoing focus on how the company manages competitive pressure at the lower end of the market.Narrative Update • Apr 21
SKIN: Future Returns Will Rely On FY26 EBITDA Delivery Despite Macro Pressures
Analysts trimmed Beauty Health's price target by $0.15 to $1.50, citing updated models after Q4 results where revenue was lower but ahead of expectations, FY26 EBITDA guidance points to upside versus current Street estimates, and softer near term distributor orders tied to macro pressure. Analyst Commentary Recent commentary highlights a mixed read on Beauty Health, with analysts weighing long term profit guidance against near term demand headwinds and a slightly lower price target of US$1.50.Narrative Update • Apr 07
SKIN: Future Returns Will Be Supported By FY26 EBITDA Guidance Delivery
Analysts have trimmed Beauty Health's price target by $0.15 to $1.50 as they refresh models after Q4 results that showed revenue down but ahead of expectations, with updated EBITDA guidance for FY26 and softer near term distributor ordering under macro pressure helping to shape their outlook. Analyst Commentary Recent research paints a mixed picture for Beauty Health, with analysts updating models after Q4 and revisiting fair value as they factor in near term pressure on distributor orders alongside longer term profitability targets.Narrative Update • Mar 24
SKIN: Future Returns Will Be Supported By FY26 EBITDA Upside Potential
The analyst price target for Beauty Health has been reduced by $0.15 to $1.50, as analysts factor in softer near term distributor ordering after Q4 revenue came in down but ahead of expectations, alongside FY26 EBITDA guidance that they view as implying roughly 20% upside versus the Street. Analyst Commentary Analysts are recalibrating their views on Beauty Health after the Q4 report, focusing on the tension between softer near term trends and what they see in the company’s longer term EBITDA guidance.Narrative Update • Mar 10
SKIN: Updated Governance And Margin Execution Will Support Future Upside
Analysts have nudged their price target for Beauty Health higher to $3.50, citing slightly stronger assumptions around revenue growth, profit margins, and a modestly lower discount rate reflected in a small adjustment to the future P/E. Analyst Commentary Recent research points to a more constructive tone around Beauty Health, with price targets and ratings framed around what analysts see as the company’s ability to execute on its current plan rather than any major shift in its business model.Narrative Update • Feb 24
SKIN: Higher Assumed P/E And Margin Execution Will Support Future Upside
Analysts have nudged their price targets on Beauty Health higher to $3.38, reflecting updated views on risk, modest revenue expectations, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on Beauty Health has focused on how to balance risk, valuation, and execution, with some bullish analysts pointing to conditions they believe could support the higher US$3.38 price target.Analysis Article • Feb 12
It's Down 30% But The Beauty Health Company (NASDAQ:SKIN) Could Be Riskier Than It Looks
The Beauty Health Company ( NASDAQ:SKIN ) shareholders won't be pleased to see that the share price has had a very...Narrative Update • Feb 08
SKIN: Execution On Updated Margin Plan Will Support Future Upside
Analysts have nudged their price target on Beauty Health higher to around a fair value of US$3.38 per share, citing modest adjustments to growth, margins and future P/E assumptions reflected in recent TD Cowen and Jefferies research. Analyst Commentary Recent Street research around Beauty Health has centered on modestly higher valuation markers and a reaffirmation of a more wait and see stance on the shares.Analysis Article • Feb 06
Is Beauty Health (NASDAQ:SKIN) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Jan 25
SKIN: Improved Execution And Buyback Progress Will Support Future Upside
Analysts have inched their average price target for Beauty Health higher by US$0.15, reflecting updated views on growth, margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish analysts are framing the US$0.15 increase in the average price target as a sign that recent updates to growth and margin expectations still support the current valuation, even with a slightly lower assumed future P/E multiple.Narrative Update • Jan 11
SKIN: Future Returns Will Be Supported By Stable Margins And Completed Buyback Program
Analysts have modestly adjusted their price target on Beauty Health, citing small tweaks to the discount rate, revenue growth expectations, profit margin assumptions and forward P/E multiples. Together, these changes support a refined valuation framework rather than a major reset in outlook.Narrative Update • Dec 27
SKIN: Share Repurchase And New CEO Are Expected To Drive Upside
Analysts have modestly raised their price target on Beauty Health, reflecting a move in fair value from approximately 2.00 dollars to about 3.38 dollars. They factor in slightly stronger long term revenue growth expectations alongside a higher future earnings multiple, partially offset by a marginally lower projected profit margin and a slightly higher discount rate.Narrative Update • Dec 13
SKIN: Future Returns Will Be Driven By Improved Device Churn Management
Analysts modestly raised their price target on Beauty Health to $2.50 from $2.00, citing early evidence that the CEO's reset is helping manage device churn, spur consumables innovation, and deepen engagement across its 35,000 strong installed base. Analyst Commentary Analysts are reacting to the updated outlook with a balanced tone, reflecting both improving fundamentals and lingering execution risks that cap near term upside.Narrative Update • Nov 29
SKIN: Future Growth Will Be Driven By Improved Churn Management
Analysts have raised their price target for Beauty Health from $2.00 to $2.50. They cite improved management of device sales, consumables innovation, and deeper provider engagement as key factors supporting the company's outlook.Analysis Article • Nov 27
Is There An Opportunity With The Beauty Health Company's (NASDAQ:SKIN) 35% Undervaluation?
Key Insights The projected fair value for Beauty Health is US$2.24 based on 2 Stage Free Cash Flow to Equity Current...Narrative Update • Nov 15
SKIN: Future Revenue Will Be Driven By Improved Device Sales Management
Analysts have increased their price target for Beauty Health from $2.00 to $2.50. They cite improved device sales management, innovation in consumables, and deeper provider engagement as drivers for this positive outlook.Analysis Article • Oct 14
The Market Doesn't Like What It Sees From The Beauty Health Company's (NASDAQ:SKIN) Revenues Yet As Shares Tumble 40%
The Beauty Health Company ( NASDAQ:SKIN ) shares have had a horrible month, losing 40% after a relatively good period...Narrative Update • Sep 20
Premium Beauty Markets Will Face Risks And Rewards
Beauty Health’s consensus price target has increased notably as the market now assigns a higher future P/E multiple despite a slight decline in net profit margin, reflecting increased investor optimism and raising the fair value estimate from $1.88 to $2.17. What's in the News Completed repurchase of 10,350,749 shares (7.81%) for $30.18 million; no shares repurchased in the latest tranche.Analysis Article • Aug 30
The Beauty Health Company's (NASDAQ:SKIN) 30% Price Boost Is Out Of Tune With Revenues
The The Beauty Health Company ( NASDAQ:SKIN ) share price has done very well over the last month, posting an excellent...Narrative Update • Aug 08
Premium Beauty Markets Will Face Risks And Rewards
The upward revision in Beauty Health’s consensus price target to $1.75 is primarily driven by a substantial increase in revenue growth forecasts and a lower discount rate, signaling improved growth expectations and a more favorable risk profile. What's in the News Company updated earnings guidance, projecting Q3 net sales of $65–$70 million and full-year net sales of $285–$300 million, citing strong first half performance.Analysis Article • May 11
Analysts Are Updating Their The Beauty Health Company (NASDAQ:SKIN) Estimates After Its First-Quarter Results
A week ago, The Beauty Health Company ( NASDAQ:SKIN ) came out with a strong set of first-quarter numbers that could...Analysis Article • Apr 11
The Beauty Health Company (NASDAQ:SKIN) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, The Beauty Health Company ( NASDAQ:SKIN ) shares are down a considerable 26% in...
New Narrative • Apr 02
Sales Execution And Hydralock Booster Launch Will Strengthen Future Prospects
Operational improvements and strategic market positioning are set to enhance profitability and boost revenue growth.Analysis Article • Mar 14
The Beauty Health Company (NASDAQ:SKIN) Analysts Just Cut Their EPS Forecasts Substantially
Market forces rained on the parade of The Beauty Health Company ( NASDAQ:SKIN ) shareholders today, when the analysts...Analysis Article • Feb 27
Is Beauty Health (NASDAQ:SKIN) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Dec 27
The Beauty Health Company (NASDAQ:SKIN) Doing What It Can To Lift Shares
The Beauty Health Company's ( NASDAQ:SKIN ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a buy right...Analysis Article • Oct 18
Health Check: How Prudently Does Beauty Health (NASDAQ:SKIN) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Aug 06
Positive Sentiment Still Eludes The Beauty Health Company (NASDAQ:SKIN) Following 33% Share Price Slump
To the annoyance of some shareholders, The Beauty Health Company ( NASDAQ:SKIN ) shares are down a considerable 33% in...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 313 | -11 | 6 | 30 | 3 |
| 12/31/2027 | 305 | -11 | 13 | 19 | 8 |
| 12/31/2026 | 290 | -22 | 7 | 1 | 9 |
| 3/31/2026 | 296 | -7 | 23 | 29 | N/A |
| 12/31/2025 | 301 | -10 | 32 | 37 | N/A |
| 9/30/2025 | 302 | -12 | 34 | 39 | N/A |
| 6/30/2025 | 310 | -19 | 34 | 39 | N/A |
| 3/31/2025 | 322 | -39 | 30 | 36 | N/A |
| 12/31/2024 | 334 | -29 | 9 | 16 | N/A |
| 9/30/2024 | 348 | -28 | -14 | -6 | N/A |
| 6/30/2024 | 366 | -84 | -8 | 2 | N/A |
| 3/31/2024 | 393 | -81 | 6 | 18 | N/A |
| 12/31/2023 | 398 | -100 | -10 | 22 | N/A |
| 9/30/2023 | 399 | -84 | -11 | 22 | N/A |
| 6/30/2023 | 391 | -10 | -63 | -28 | N/A |
| 3/31/2023 | 377 | -7 | -118 | -81 | N/A |
| 12/31/2022 | 366 | 44 | -125 | -107 | N/A |
| 9/30/2022 | 346 | 20 | -123 | -98 | N/A |
| 6/30/2022 | 325 | -195 | -85 | -66 | N/A |
| 3/31/2022 | 288 | -340 | -86 | -68 | N/A |
| 12/31/2021 | 260 | -379 | -44 | -28 | N/A |
| 9/30/2021 | 220 | -365 | -40 | -32 | N/A |
| 6/30/2021 | 186 | -152 | -40 | -33 | N/A |
| 3/31/2021 | 134 | -23 | N/A | N/A | N/A |
| 12/31/2020 | 119 | -29 | -16 | -12 | N/A |
| 9/30/2020 | 131 | -19 | -12 | -3 | N/A |
| 12/31/2019 | 167 | -2 | N/A | 2 | N/A |
| 12/31/2018 | 112 | -91 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SKIN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SKIN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SKIN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SKIN's revenue (2.2% per year) is forecast to grow slower than the US market (12.8% per year).
High Growth Revenue: SKIN's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SKIN's Return on Equity is forecast to be low in 3 years time (9.5%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/17 00:48 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SkinHealth Systems Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Navann Ty Dietschi | BNP Paribas |
| Susan Anderson | Canaccord Genuity |